Boundless Bio (BOLD) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 01We have a limited operating history, have incurred significant operating losses since our inception, and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it
2. 02We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our ecDTx development programs, commercialization efforts or other operations
3. 03costs associated with any products or technologies that we may in-license or acquire
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or ecDTx

Risks Related to the Discovery, Development, and Regulatory Approval of Our ecDTx

1. 05acceptance of our products, if approved, by patients, the medical community, and third-party payors
2. 06Our approach to treating cancer with oncogene amplifications by developing ecDTx directed against ecDNA is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing approaches will limit the commercial value of our ecDTx
3. 07of our ecDTx. Further, because our current ecDTx and all of our discovery programs are ecDNA based, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs
4. 08If any of these events occur, we may be forced to delay, modify, or abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations
5. 09Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or planned clinical trials or preclinical studies could result in increased costs to us, delay or limit our ability to generate revenue, or adversely affect our commercial prospects
6. 10third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner
7. 11We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties or delays enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 12our reputation may suffer
9. 13As an organization, we have never completed any clinical trials and may be unable to do so for any of our ecDTx
10. 14If we are unable to successfully develop an ecDNA diagnostic to enable patient selection for our ecDTx, or if we experience significant delays in doing so, we may not realize the full commercial potential of our ecDTx
11. 15We intend to develop our ecDTx in combination with other therapies, which exposes us to additional risks
12. 16If the FDA or similar foreign regulatory authorities revoke the approval of combination agents, or if safety, efficacy, manufacturing, or supply issues arise with the drugs we choose to evaluate in combination with our ecDTx, we may be unable to obtain approval of or market our ecDTx for combination therapy regimens
13. 17We may expend our limited resources to pursue a particular ecDTx or a particular indication for an ecDTx and fail to capitalize on ecDTx or indications that may be more profitable or for which there is a greater likelihood of success
14. 18We may in the future conduct certain of our clinical trials for our ecDTx outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business
15. 19Interim, topline, and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
16. 20Changes in methods of ecDTx manufacturing or formulation may result in additional costs or delay
17. 21negotiating insurance reimbursement plans, all of which may prevent us from completing our clinical trials or commercializing our ecDTx, if approved, on a timely or profitable basis, if at all

Risks Related to Our Reliance on Third Parties

1. 22or products or such quantities at an acceptable cost, which could delay, prevent, or impair, our development or commercialization efforts
2. 23in the event of approval to market and commercialize our ecDTx, an inability to meet commercial demands for our ecDTx
3. 24Our ecDTx and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities
4. 25Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover them or that our trade secrets will be misappropriated or disclosed
5. 26We may seek to enter into collaborations, licenses, and other similar arrangements and may not be successful in doing so, and even if we are, we may relinquish valuable rights and may not realize the benefits of such relationships

Risks Related to Commercialization of Our ecDTx

1. 27Even if we receive regulatory approval for any ecDTx, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense
2. 28The occurrence of any event or penalty described above may inhibit our ability to commercialize our ecDTx and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
3. 29The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
4. 30The commercial success of our ecDTx will depend upon the degree of market acceptance of such ecDTx by physicians, patients, healthcare payors, and others in the medical community
5. 31unfavorable publicity relating to the product
6. 32The market opportunities for our ecDTx may be limited to patients who are ineligible for or have failed prior treatments and may be small or different from our estimates
7. 33Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

Risks Related to Our Business Operations and Industry

1. 34Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
2. 35the timing and amount of any milestone, royalty, or other payments payable by us or due to us under any collaboration, licensing, or other similar agreement
3. 36Our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personnel
4. 37We may encounter difficulties in managing our growth and expanding our operations successfully
5. 38We are subject to various U.S. federal, state, and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business
6. 39Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us to obtain coverage for and commercialize our ecDTx and may adversely affect the prices we may set
7. 40If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit, delay, or cease commercialization of our ecDTx
8. 41a decline in our stock price
9. 42Our insurance policies are expensive and protect us from only some business risks, which will leave us exposed to significant uninsured liabilities
10. 43legislation in the United States. In the event that we are subject to or affected by HIPAA, the CCPA, or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition
11. 44contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity, and adversely affect our business, financial condition, results of operations, and prospects
12. 45Our business is subject to risks arising from pandemic and epidemic diseases
13. 46Our business could be affected by litigation, government investigations, and enforcement actions
14. 47Our employees and independent contractors, including principal investigators, CROs, consultants, and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
15. 48We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management
16. 49Our ability to use net operating loss carryforwards and other tax attributes may be limited
17. 50Inflation could adversely affect our business and results of operation

Risks Related to Our Intellectual Property

1. 51we are unable to obtain, maintain, expand, enforce, and defend the scope of our intellectual property protection, our business, financial condition, results of operations, and prospects could be materially harmed
2. 52We may not be able to protect our intellectual property and proprietary rights throughout the world
3. 53Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
4. 54Changes in patent laws or their interpretations could diminish the value of patents in general, thereby impairing our ability to protect our products
5. 55Issued patents covering our ecDTx could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
6. 56Patent terms may be inadequate to protect the competitive position of our ecDTx for an adequate amount of time
7. 57If we do not obtain patent term extension and equivalent extensions outside of the United States for our ecDTx, our business may be materially harmed
8. 58We may be subject to claims challenging the inventorship of our patents and other intellectual property
9. 59If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
10. 60We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
11. 61We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop and market our products and ecDTx
12. 62Third-party claims of intellectual property infringement, misappropriation, or other violations against us or our collaborators could be expensive and time consuming and may prevent or delay the development and commercialization of our ecDTx
13. 63to claims of patent infringement, we cannot be certain that we would prevail in any dispute, and we cannot be certain how an adverse determination would affect our business
14. 64We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming, and unsuccessful
15. 65If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest, and our business may be adversely affected
16. 66Intellectual property rights do not necessarily address all potential threats
17. 67the patents or other intellectual property rights of others may harm our business; and
18. 68We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses

Risks Related to Ownership of Our Common Stock

1. 69An active, liquid, and orderly market for our common stock may not be sustained, or we may in the future fail to satisfy the continued listing requirements of Nasdaq
2. 70shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business
3. 71The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses
4. 72changes in accounting standards, policies, guidelines, interpretations, or principles
5. 73Our executive officers, directors, and principal stockholders, if they choose to act together, have the ability to significantly influence all matters submitted to stockholders for approval
6. 74We do not currently intend to pay dividends on our common stock, so any returns on your investment will be limited to the value of our common stock
7. 75Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall
8. 76We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
9. 77exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved
10. 78Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
11. 79We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
12. 80Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences
13. 81We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials could be time-consuming or costly
14. 82Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
15. 83Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition, and stock price
16. 84Changes in tax law may materially adversely affect our financial condition, results of operations and cash flows, or adversely impact the value of an investment in our common stock
17. 85If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
18. 86If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting, and the trading price of our common stock may decline
19. 87We could be subject to securities class action litigation